Vitamin D Eksikliği ile Endotel Disfonksiyon Göstergelerinden Serum Endocan ve Asymetric Dimetil Arginin (ADMA) Düzeylerı̇ Arasındaki İlişki

Yıl 2020, Cilt: 25 Sayı: 2, 112 - 119, 13.06.2020

Selin Yurdakul Mustafa Çakırca , Ömer Faruk Özer , İskender Ekinci Elif Ece Doğan Cumali Karatoprak

https://doi.org/10.21673/anadoluklin.626396

Öz

Giriş: Son zamanlarda D vitamini eksikliğinin kemik metabolizma hastalıkları dışında, alzheimer, parkinson, multiple sklerozis, diyabet, kardiyovasküler hastalıklar gibi pek çok hastalığın oluşmasında rolü olabileceğini destekleyen çalışmalar artmaktadır. Biz de çalışmamızda D vitamini düzeyinin, kardiyovasküler erken risk belirteçleri olarak kabul edilen serum endocan ve ADMA düzeyleri arasındaki ilişkiyi araştırmayı amaçladık.

Materyal- Metod: Çalışmada Vitamin D düzeyi <10 ng/ml olan 42 kişi (grup 1) ve vitamin D düzeyi > 30 ng/ml olan 35 kişiden (grup2) oluşan iki grup oluşturuldu. Grupların VKİ, serum vitamin D, Endocan, ADMA, PTH, TSH, Glikoz, HOMA-IR, HDL kolesterol, LDL kolesterol, Trigliserit, düzeyleri karşılaştırıldı.

Bulgular: Çalışmaya dahil edilen toplam 77 hastanın sonuçları karşılaştırıldı. Her iki grubun yaş, cinsiyet ve BMI değerleri karşılaştırıldığında anlamlı fark olmadığı saptandı (sırasıyla p:0.67, p:0.69, p:0.052). Grup 1 de serum ADMA düzeyi 104.5 ± 44 μmol/L olarak, grup 2’de 90.42 ± 29 μmol/L tespit edildi (p:0.31). Endocan düzeyi ise grup 1’de 549.5 ± 245 ng/L ve grup 2’de 465.99 ± 207 ng/L tespit edildi (p:0.12). Vitamin D düzeyi ile endocan düzeyi arasında anlamlı negatif korelâsyon saptandı (r:-0.26 p:0.02). Serum endocan ve ADMA arasında da anlamlı bir korelâsyon izlenmedi (r:0.19, p:0.1). Gruplar arası PTH, ALT, ALP, HDL kolesterol ve Trigliserit düzeylerinde istatistiksel olarak anlamlı fark tespit edilirken diğer parametrelerde anlamlı olarak fark tespit edilemedi.

Sonuç: Kardiyovasküler riski değerlendirmek üzere endotel disfonksiyonu göstergelerinden serum endocan ve ADMA düzeylerini incelediğimiz çalışmada vitamin D düşüklüğü olan hastalarda anlamlı bir değişim saptamadık. Bu parametreler üzerinden yalnızca vitamin D düşüklüğünün endotel disfonksiyonu üzerine bir etki saptayamadığımızı söyleyebiliriz. Ancak çalışma sınırlı sayıda gönüllü ile yapıldığından daha kesin sonuçlara ulaşmak için daha büyük çalışmalara ihtiyaç olduğunu düşünüyoruz.

Anahtar Kelimeler

Vitamin D eksikliği, Endotelial disfonksiyon, ADMA

Destekleyen Kurum

Yok

The relationship between vitamin D deficiency and serum endocan and asymetric dimethylarginine levels, indicators of endothelial dsyfunction

Öz

Backround: Recently, studies support that the lack of vitamin D deficiency may play a role in the pathogenesis of many diseases such as alzheimer, Parkinson, multiple sclerosis, diabetes mellitus, cardiovascular diseases.

Objectives: We aimed to investigate the relationship between vitamin D levels and serum endocan and ADMA levels, which are accepted as cardiovascular early risk markers, by determining vitamin D levels in patients without known chronic disease history in our study.

Material and Method: According to Vitamin D levels, we divided patients into two groups as; Vitamin D <10 ng/ml (Group 1) ve vitamin D level > 30 ng/ml (Group 2) to investigate. Levels of BMI, serum Vitamin D, Endocan, ADMA of the groups were compared.

Results: The results of a total of 77 patients included in the study were compared. There was no significant difference in age, gender and BMI between the two groups (p: 0.67, p: 0.69, p: 0.052, respectively). Serum ADMA levels were determined as 104.5 ± 44 μmol / L in group 1 and 90.42 ± 29 μmol / L in group 2 (p: 0.31). Endocan levels were 549.5 ± 245 ng / L in group 1 and 465.99 ± 207 ng / L in group 2 (p: 0.12). There was a significant negative correlation between vitamin D levels and endocan levels (r: -0.26 p: 0.02).

Conclusion: In this study which we examined serum endocan and ADMA levels from endothelial dysfunction indicators to assess cardiovascular risk, we did not find a significant change in patients with low vitamin D levels. Based on these parameters, we can say that only vitamin D deficiency has no effect on endothelial dysfunction.

Anahtar Kelimeler

Vitamin D deficiency, Endothelial Dysfunction, ADMA

Kaynakça

• 1. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94:26-34.
• 2. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49.
• 3. Mozos I, Marginean O. Links between Vitamin D Deficiency and Cardiovascular Diseases. Biomed Res Int 2015;2015:109275.
• 4. Tousoulis D, Georgakis MK, Oikonomou E, et al. Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches. Curr Med Chem 2015;22:2871-901.
• 5. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015;243:339-43.
• 6. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-48S.
• 7. Schwalfenberg G. Not enough vitamin D: health consequences for Canadians. Can Fam Physician 2007;53:841-54.
• 8. Haliloglu O, Kasaci T, Yavuz D. Seasonal vitamin D status and endothelial function in healthcare workers. Turk J Med Sci 2016;46:72-8.
• 9. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-6.
• 10. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005;48:1247-57.
• 11. Abbas MA. Physiological functions of Vitamin D in adipose tissue. J Steroid Biochem Mol Biol 2017;165:369-81.
• 12. Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008;88:558S-64S.
• 13. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010;39:381-400, table of contents.14. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-20.
• 15. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.
• 16. Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Res 2008;23:974-9.
• 17. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035.
• 18. Al Mheid I, Patel RS, Tangpricha V, Quyyumi AA. Vitamin D and cardiovascular disease: is the evidence solid? Eur Heart J 2013;34:3691-8.
• 19. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493 e1-8.
• 20. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006;58:159-78.
• 21. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Am J Med 2010;123:335-41.
• 22. Abu El Maaty MA, Hassanein SI, Hanafi RS, Gad MZ. Insights on vitamin D's role in cardiovascular disease: investigating the association of 25-hydroxyvitamin D with the dimethylated arginines. J Nutr Sci Vitaminol (Tokyo) 2013;59:172-7.
• 23. Gungor A, Palabiyik SS, Bayraktutan Z, et al. Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidisim. Endocr Res 2016;41:275-80.
• 24. Atis O, Keles M, Cankaya E, Dogan H, Aksoy H, Akcay F. Vitamin D Treatment Effect on Serum Endocan and High-Sensitivity C-Reactive Protein Levels in Renal Transplant Patients. Prog Transplant 2016;26:335-9.
• 25. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.